Viral vectors having reduced virulence

• US 20020155529A1
• Filed: 04/19/2001
• Published: 10/24/2002
• Est. Priority Date: 04/19/2001
• Status: Active Grant

• Current Assignee: Arizona Board of Regents (University of Arizona)
• Original Assignee: Arizona Board of Regents (University of Arizona)
• Inventors: Jacobs, Bertram, Vijaysri, Sangeetha, Langland, Jeffrey
• Granted Patent: US 6,750,043 B2
• Time in Patent Office: Days
• US Class Current: 435/69.1
• CPC Class Codes: A61K 2039/5256 expressing foreign proteins
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/24134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2710/24143 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2710/24161 Methods of inactivation or attenuation
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00
• CPC Class Codes: C12P 21/02 having a known sequence of two or more amino acids, e.g. glutathione

Abstract

The present invention provides recombinant vaccinia virus having a deletion of the region encoding the C-terminal seven amino acids of the E3L gene product and comprising exogenous DNA. Compositions comprising the recombinant vaccinia virus and methods of use thereof are also provided.

Claims

1. An expression vector comprising a vaccinia virus having a deletion of the region encoding amino acids 184-190 of the E3L gene product wherein said vector further comprises exogenous DNA operably linked to regulatory elements that control expression of said exogenous DNA.

2. The expression vector of claim 1 wherein said exogenous DNA encodes an antigen.

3. The expression vector of claim 1 in which one or more non-essential virus-encoded gene functions have been deleted from the vaccinia virus.

4. A composition comprising the expression vector of claim 1 and a carrier.

5. A method of making a recombinant gene product comprising subjecting an expression vector comprising a vaccinia virus having a deletion of the region encoding amino acids 184-190 of the E3L gene product and wherein said vector further comprises exogenous DNA that encodes said recombinant gene product operably linked to regulatory elements that control expression thereof, to conditions whereby said recombinant gene product is expressed.

6. The method of claim 5 further comprising recovering said recombinant gene product.